News|Videos|February 8, 2017

Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia

This video examines frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia, including considerations for when chemotherapy or ibrutinib might be more appropriate.

In this video, Susan O’Brien, MD, of the University of California Irvine Medical Center, discusses frontline treatment options for patients with newly diagnosed chronic lymphocytic leukemia (CLL). In order to provide personalized therapy for patients, certain factors may determine whether chemotherapy or ibrutinib would be the more appropriate option.

Dr. O’Brien also discusses novel agents approved as second-line therapies for CLL and side effect profiles physicians should consider when recommending treatment.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!

Latest CME

In-Person + Virtual Event

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

October 26, 2025

Chemotherapy vs Ibrutinib for Frontline Treatment of Chronic Lymphocytic Leukemia

Newsletter

Related Content

FDA Approves Revumenib in R/R NPM1-Mutant AML

FDA Accepts NDA for New Nilotinib Formulation in CML

FDA Issues CRL for Dasatinib in CML/ALL

Translating CLL Trial Success to Real-World Treatment Application

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Latest CME

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Iowa

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | New York

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Minnesota

20th Annual New York Lung Cancers Symposium®

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Texas

Community Oncology Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy – Strategies for the Multidisciplinary Team | Washington

Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances

Advances In™: Taking R/R B-Cell ALL Management to the Next Level With New CAR T Approval

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care

Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer

Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials

Annual Hematology Meeting: Preceding the 67th ASH Annual Meeting and Exposition

Breast Cancer Symposia in San Antonio

Burst CME™: How is the Newly Approved CAR T-Cell Therapy Impacting R/R B-Cell ALL Management?

Evolving Strategies and Emerging Agents in PTCL: Subtypes, Mutations, and Modern Therapies

Epithelioid Sarcoma: Applying Clinical Updates to Real Patient Cases

Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care

Collaborating Across the Continuum®: Identifying and Treating Epithelioid Sarcoma

Mastering Epithelioid Sarcoma: Enhancing Diagnostic Precision and Tailoring Treatment Strategies

Clinical Showcase™: Selecting the Best Next Steps for a Patient with Epithelioid Sarcoma

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

2nd Annual Hawaii Cancer Conference

Medical Crossfire®: Bridging Evidence to Practice in AML…Updates on FLT3, IDH1/2, Maintenance, Combos, and Clinical Trials

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

19th Annual New York GU Cancers Congress™

Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

11th Annual School of Gastrointestinal Oncology® (SOGO®)

Addressing Unmet Needs in HER2+ Metastatic BTC

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Proactive Adverse Event Management for HER2+ BTC Treatments

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Optimizing Treatment for Biliary Tract Cancers

Cross-Disease Integration of Immunotherapy Innovations

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Radioligand Therapy 101: The Science Behind the Strategy